Intest Res.  2024 Apr;22(2):117-118. 10.5217/ir.2024.0043.

Achieving high-quality magnetic resonance enterography is critical for assessing Crohn’s disease activity

• Song KD

• KMID: 2554656
• DOI: http://doi.org/10.5217/ir.2024.0043

Reference

1. Cicero G, Mazziotti S. Crohn’s disease at radiological imaging: focus on techniques and intestinal tract. Intest Res. 2021; 19:365–378.

2. Rimola J, Rodriguez S, García-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009; 58:1113–1120.

3. Ordás I, Rimola J, Alfaro I, et al. Development and validation of a simplified magnetic resonance index of activity for Crohn’s disease. Gastroenterology. 2019; 157:432–439.

4. Steward MJ, Punwani S, Proctor I, et al. Non-perforating small bowel Crohn’s disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index. Eur J Radiol. 2012; 81:2080–2088.

5. Bohra A, Connoley DJ, Con D, et al. Assessing quality of magnetic resonance enterography and its impact on disease assessment of ileal Crohn’s disease. Intest Res. 2024; 22:152–161.

6. Gutzeit A, Binkert CA, Koh DM, et al. Evaluation of the antiperistaltic effect of glucagon and hyoscine on the small bowel: comparison of intravenous and intramuscular drug administration. Eur Radiol. 2012; 22:1186–1194.

7. Froehlich JM, Daenzer M, von Weymarn C, Erturk SM, Zollikofer CL, Patak MA. Aperistaltic effect of hyoscine N-butylbromide versus glucagon on the small bowel assessed by magnetic resonance imaging. Eur Radiol. 2009; 19:1387–1393.